纤溶酶原激活物及其抑制剂-1的血浆含量测定在急性肺血栓栓塞症中的意义

Value of measuring plasma concentration of plasminogen activator and its inhibitor-1 in acute pulmonary thromboembolism

目的 探讨在急性肺血栓栓塞症 (APE)发病中的组织型纤溶酶原激活物 (tPA)及其抑制剂 1(PAI 1)的血浆含量、作用及其该病诊断中的意义。方法 对 4 4例APE患者和 5 6例健康正常对照者应用酶联免疫吸附双抗体夹心法 (ELISA法 )定量测定血浆tPA和PAI 1抗原水平。结果 与正常对照组 (tPA含量为 11 0 5ng/ml和PAI 1含量为 6 1 31ng/ml)相比 ,APE组的tPA含量 (33 88ng/ml)和PAI 1含量(111 5 0ng/ml)较高 ,两组间差异有显著性。在急性肺血栓栓塞症的疾病诊断中 ,tPA和PAI 1的血浆含量合理诊断截断点分别为 2 1 7ng/ml和 79 4ng/ml。结论 急性肺血栓栓塞症的发病是由于PAI l抗原产生和释放增多 ,而非tPA抗原释放或产生不足所致。tPA和PAI

Objective To investigate the significance of plasminogen activator(tPA) and plasminogen activator inhibitor-1(PAI-1)in acute pulmonary thromboembolism(APE).Methods The levels of PAI-1 and tPA were measured by a commercially available enzyme-linked immunosorbent assay(ELISA)in 44 APE patients and 56 health control persons.Results Compared with tPA 11.05 ng/ml and PAI-1 antigen 61.31 ng/ml in healthy control group,APE patients had higher levels of tPA antigen 33.88 ng/ml and PAI-1 antigen 111.50 ng/ml.In the diagnosis of pulmonary thromboembolism,tPA 21.7 ng/ml and PAI-1 79.4 ng/ml were the cut-off points.Conclusion Increased PAI-1 level in plasma may cause APE.The determination of tPA and PAI-1 concentrations in plasma plays an important role in the diagnosis of APE.